Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Cancer immunology research - 1 Mar 2015

Johnson Douglas B, Lovly Christine M, Flavin Marisa, Panageas Katherine S, Ayers Gregory D, Zhao Zhiguo, Iams Wade T, Colgan Marta, DeNoble Sarah, Terry Charles R, Berry Elizabeth G, Iafrate A John, Sullivan Ryan J, Carvajal Richard D, Sosman Jeffrey A

Abstract excerpt

Activating NRAS mutations are found in 15% to 20% of melanomas. Immune therapies have become a mainstay in advanced melanoma treatment. We sought to evaluate whether tumor genotype (e.g., NRAS mutations) correlates with benefit from immune therapy in melanoma. We identified 229 patients with melanoma treated with immune therapies [IL2, ipilimumab, or anti-programmed cell death-1/ligand-1 (PD-1/PD-L1)] at three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Interleukin-2

Share to Ipilimumab

Share to Melanoma

Share to Membrane Proteins

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 25736262
DOI: 10.1158/2326-6066.CIR-14-0207
PMCID: PMC4351797

Genes

NRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.PMID 25736262Read ↗

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.Semantic proximity Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.Semantic proximity Read ↗

NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.Semantic proximity Read ↗

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.Semantic proximity Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.Semantic proximity Read ↗

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.Semantic proximity Read ↗

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.Semantic proximity Read ↗

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.Semantic proximity Read ↗

Treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.